Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gallagher

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Nature Communications|January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repairAyesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
BMC Psychiatry|August 7, 2013
Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)R Hamish McAllister-Williams, Eleanor Smith, Ian M Anderson, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Wellcome Open Research|February 23, 2021
Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO)Nguyet Minh Nguyen, Ho Quang Chanh, Dong Thi Hoai Tam, et al.
Bipolar Disorders|September 7, 2019
Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task forceKamilla W Miskowiak, Ida Seeberg, Hanne L Kjaerstad, et al.
Cancer Discovery|April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced DiseaseAmy C Mandigo, Wei Yuan, Kexin Xu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A Ketogenic Diet Sensitizes Pancreatic Cancer to Inhibition of Glutamine MetabolismOmid Hajihassani, Mehrdad Zarei, Asael Roichman, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Arthritis Care & Research|December 20, 2016
Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the DiscrepancyOriana M Bezzina, Peter Gallagher, Sheryl Mitchell, et al.
Bipolar Disorders|August 11, 2022
Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task ForceKamilla W Miskowiak, Nefize Yalin, Ida Seeberg, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Nature Communications|January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repairAyesha A Shafi, Chris M McNair, Jennifer J McCann, et al.
BMC Psychiatry|August 7, 2013
Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)R Hamish McAllister-Williams, Eleanor Smith, Ian M Anderson, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Wellcome Open Research|February 23, 2021
Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO)Nguyet Minh Nguyen, Ho Quang Chanh, Dong Thi Hoai Tam, et al.
Bipolar Disorders|September 7, 2019
Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task forceKamilla W Miskowiak, Ida Seeberg, Hanne L Kjaerstad, et al.
Cancer Discovery|April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced DiseaseAmy C Mandigo, Wei Yuan, Kexin Xu, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2024
A Ketogenic Diet Sensitizes Pancreatic Cancer to Inhibition of Glutamine MetabolismOmid Hajihassani, Mehrdad Zarei, Asael Roichman, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Arthritis Care & Research|December 20, 2016
Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the DiscrepancyOriana M Bezzina, Peter Gallagher, Sheryl Mitchell, et al.
Bipolar Disorders|August 11, 2022
Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task ForceKamilla W Miskowiak, Nefize Yalin, Ida Seeberg, et al.
Pageof 17